Alessandra Mangia Selected Research

velpatasvir

1/2021	Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
11/2020	Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
1/2019	SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
1/2019	SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
1/2019	Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
1/2018	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
1/2017	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
12/2016	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
10/2016	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
1/2016	Sofosbuvir and Velpatasvir for Patients with HCV Infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandra Mangia Research Topics

Disease

34	Infections 01/2022 - 01/2006
30	Fibrosis (Cirrhosis) 01/2022 - 03/2007
22	Chronic Hepatitis C 01/2022 - 07/2002
11	Hepatitis C 01/2022 - 01/2008
10	Liver Diseases (Liver Disease) 11/2020 - 05/2013
8	Hepatocellular Carcinoma (Hepatoma) 06/2021 - 05/2007
6	Chronic Hepatitis B 01/2021 - 10/2002
5	Hepatitis 01/2019 - 07/2002
5	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019 - 06/2009
4	COVID-19 11/2021 - 11/2020
4	Non-alcoholic Fatty Liver Disease 06/2021 - 01/2016
4	Neoplasms (Cancer) 01/2015 - 08/2011
3	Fatigue 01/2017 - 05/2013
2	Fatty Liver 01/2020 - 05/2005
2	Inflammation (Inflammations) 01/2019 - 01/2017
2	Chronic Hepatitis (Chronic Active Hepatitis) 01/2019 - 07/2002
2	Chronic Disease (Chronic Diseases) 01/2017 - 10/2016
2	Body Weight (Weight, Body) 12/2010 - 06/2005
1	Breakthrough Infections 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Disease Progression 06/2021
1	Alcoholic Fatty Liver 06/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2021
1	Hepatitis B 01/2021
1	HIV Infections (HIV Infection) 01/2020
1	Portal Hypertension 01/2019
1	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2017
1	Virus Diseases (Viral Diseases) 12/2016
1	Hemorrhage 01/2016
1	Lymphoma (Lymphomas) 01/2015
1	Cryoglobulinemia 01/2015
1	Liver Failure 08/2014
1	Type 2 Diabetes Mellitus (MODY) 07/2014

Drug/Important Bio-Agent (IBA)

27	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 07/2002
17	Antiviral Agents (Antivirals)IBA 01/2022 - 02/2009
17	SofosbuvirIBA 01/2021 - 05/2013
14	InterferonsIBA 11/2019 - 07/2002
12	velpatasvirIBA 01/2021 - 12/2015
7	VaccinesIBA 01/2022 - 01/2015
6	RNA (Ribonucleic Acid)IBA 12/2021 - 02/2009
5	Pharmaceutical PreparationsIBA 01/2022 - 08/2014
5	sofosbuvir drug combination ledipasvirIBA 01/2021 - 05/2014
4	telaprevirIBA 01/2017 - 06/2013
4	Proteins (Proteins, Gene)FDA Link 01/2015 - 05/2005
3	AntigensIBA 10/2021 - 01/2015
3	Interferon LambdaIBA 12/2020 - 08/2014
3	TabletsIBA 01/2019 - 07/2015
3	ledipasvirIBA 01/2017 - 05/2014
3	CytokinesIBA 01/2015 - 07/2010
3	NucleotidesIBA 05/2014 - 05/2013
2	Peptides (Polypeptides)IBA 01/2022 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
2	Hepatitis B e AntigensIBA 01/2019 - 01/2018
2	peginterferon alfa-2a (Pegasys)FDA Link 01/2017 - 05/2013
2	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2017 - 01/2014
2	peginterferon alfa-2b (Pegintron)FDA Link 02/2011 - 06/2005
2	Interferon-alpha (Interferon Alfa)IBA 03/2007 - 07/2002
1	Neutralizing AntibodiesIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2022
1	Opioid Analgesics (Opioids)IBA 12/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021
1	glecaprevir and pibrentasvirIBA 01/2021
1	Hepatitis C AntibodiesIBA 11/2020
1	Protons (Proton)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	Tenofovir (Viread)FDA Link 01/2019
1	ProteomeIBA 01/2019
1	micaIBA 01/2019
1	Biological ProductsIBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	vesatolimodIBA 01/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2017
1	EnzymesIBA 01/2017
1	AcyltransferasesIBA 01/2017
1	Silybin (Lagosa)IBA 04/2016
1	Genetic Markers (Genetic Marker)IBA 02/2016
1	daclatasvirIBA 01/2016
1	LipidsIBA 01/2016
1	microsomal triglyceride transfer proteinIBA 01/2016
1	rice nuclear protein GT-2 (GT-2)IBA 01/2016
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2016
1	ChemokinesIBA 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015
1	HLA-Bw6 antigenIBA 01/2015
1	HLA-Bw4 antigenIBA 01/2015
1	Liposomes (Liposome)IBA 08/2014
1	Dihydrotachysterol (AT 10)IBA 08/2014

Therapy/Procedure

28	Therapeutics 01/2022 - 10/2002
6	Duration of Therapy 01/2015 - 01/2008
3	Aftercare (After-Treatment) 01/2018 - 10/2016
2	Blood Transfusion (Blood Transfusions) 08/2014 - 01/2011
1	Liver Transplantation 06/2021
1	Withholding Treatment 01/2017
1	Opiate Substitution Treatment 12/2016
1	Contraindications 01/2016
1	Molecular Targeted Therapy 01/2015
1	Immunotherapy 01/2015